Latest & greatest articles for infliximab

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on infliximab or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on infliximab and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for infliximab

21. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model

Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model Journals Library Journals Library An error has occurred in processing the XML document An error has occurred in processing the XML document An error has occurred in processing the XML document An error occurred retrieving content to display, please try

NIHR HTA programme2016

22. Flixabi (infliximab) - rheumatoid arthritis, Crohn?s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis or psoriasis

Flixabi (infliximab) - rheumatoid arthritis, Crohn?s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis or psoriasis 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact 1 April 2016 EMA/CHMP/272283/2016 Committee for Medicinal Products for Human Use (CHMP) CHMP assessment report Flixabi International non (...) -proprietary name: INFLIXIMAB Procedure No. EMEA/H/C/004020/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. CHMP assessment report EMA/CHMP/272283/2016 Page 2/86 Administrative information Name of the medicinal product: Flixabi Applicant: Samsung Bioepis UK Limited (SBUK) Regus Building 3000 Hillswood Drive Surrey Chertsey KT16 0RS UNITED KINGDOM Active substance: INFLIXIMAB International Non-proprietary Name: INFLIXIMAB Pharmaco

European Medicines Agency - EPARs2016

23. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifyin

Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifyin Journals Library Journals Library An error has occurred in processing the XML document An error has occurred in processing the XML document An error has occurred in processing the XML document An error occurred retrieving content to display

NIHR HTA programme2016

24. Infliximab (Inflectra (Subsequent Entry Biologic))

Infliximab (Inflectra (Subsequent Entry Biologic)) Infliximab | CADTH.ca Find the information you need Infliximab Infliximab Last Updated: Result type: Reports Project Number: SE0483-000 Product Line: Generic Name: Infliximab Brand Name: Inflectra (Subsequent Entry Biologic) Manufacturer: Hospira HealthCare Corporation, a Pfizer Company Indications: Crohn’s disease and Ulcerative Colitis Submission Type: New Indication Project Status: Active Date Recommendation Issued: October 25, 2016

Canadian Agency for Drugs and Technologies in Health - Common Drug Review2016

25. Infliximab for chronic cutaneous sarcoidosis: a subset analysis from a double-blind randomized clinical trial.

Infliximab for chronic cutaneous sarcoidosis: a subset analysis from a double-blind randomized clinical trial. 26847095 2016 02 05 2016 11 02 2016 12 30 1124-0490 32 4 2016 Jan 15 Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG Sarcoidosis Vasc Diffuse Lung Dis Infliximab for chronic cutaneous sarcoidosis: a subset analysis from a double-blind randomized clinical trial. 289-95 Limited evidence exists demonstrating an effective treatment for chronic cutaneous (...) sarcoidosis. To determine infliximab's effectiveness in sarcoidosis. We conducted a subset analysis from a randomized, double-blind, placebo-controlled trial for chronic pulmonary sarcoidosis to determine infliximab's effectiveness. Patients with chronic cutaneous sarcoidosis received infliximab (3 or 5 mg/kg) or placebo over 24 weeks. Of 138 patients, the subset analysis evaluated 17 patients with chronic facial and another 9 patients with nonfacial skin involvement. The SASI evaluated lesions for degree

Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG / World Association of Sarcoidosis and Other Granulomatous Disorders2016

26. Switching from Innovator to Biosimilar (Subsequent Entry) Infliximab: Clinical Effectiveness, Cost-Effectiveness, and Guidelines

Switching from Innovator to Biosimilar (Subsequent Entry) Infliximab: Clinical Effectiveness, Cost-Effectiveness, and Guidelines Switching from Innovator to Biosimilar (Subsequent Entry) Infliximab: Clinical Effectiveness, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Switching from Innovator to Biosimilar (Subsequent Entry) Infliximab: Clinical Effectiveness, Cost-Effectiveness, and Guidelines Switching from Innovator to Biosimilar (Subsequent Entry) Infliximab (...) : Clinical Effectiveness, Cost-Effectiveness, and Guidelines Published on: November 26, 2015 Project Number: RB0939-000 Product Line: Research Type: Drug Report Type: Summary of Abstracts Result type: Report Question What is the clinical effectiveness and safety of switching from innovator infliximab to subsequent entry infliximab for patients with rheumatoid arthritis? What is the clinical effectiveness and safety of switching from innovator infliximab to subsequent entry infliximab for patients

Canadian Agency for Drugs and Technologies in Health - Rapid Review2015

27. Early Prognostic Factors Associated with the Efficacy of Infliximab Treatment for Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate

Early Prognostic Factors Associated with the Efficacy of Infliximab Treatment for Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate 27747509 2018 11 13 2198-6576 3 1 2016 Jun Rheumatology and therapy Rheumatol Ther Early Prognostic Factors Associated with the Efficacy of Infliximab Treatment for Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate. 155-166 10.1007/s40744-015-0022-y Early prognostic factors for the clinical response in patients (...) with rheumatoid arthritis (RA) after 1 year of treatment with infliximab (IFX) as part of routine clinical practice were investigated. Thirty-five patients with RA with an inadequate response to methotrexate were enrolled and administered IFX (3-9 mg/kg, every 4-8 weeks). Serum trough levels of IFX and levels of 9 cytokines were measured at baseline and at 3, 6 months, and 1 year. Associations between these parameters and clinical indicators were statistically analyzed. Serum trough levels of IFX and serum

Rheumatology and therapy2015 Full Text: Link to full Text with Trip Pro

28. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease

Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease 25724455 2015 05 26 2015 08 04 2015 11 19 1528-0012 148 7 2015 Jun Gastroenterology Gastroenterology Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. 1320-9.e3 10.1053/j.gastro.2015.02.031 S0016-5085(15)00253-X Infliximab, a tumor necrosis factor antagonist, is effective for treating patients with Crohn's disease (CD) and ulcerative colitis (UC). We aimed (...) to determine whether dosing based on therapeutic drug monitoring increases rate of remission and whether continued concentration-based dosing is superior to clinically based dosing of infliximab for maintaining remission in patients with CD and UC. We performed a 1-year randomized controlled trial at a tertiary referral center, including 263 adults (178 with CD and 85 with UC) with stable responses to maintenance infliximab therapy. Doses were escalated or reduced using an algorithm to reach a target

EvidenceUpdates2015

29. Infliximab (Remsima®)

Infliximab (Remsima®) Infliximab (Remsima®) Infliximab (Remsima®) All Wales Medicines Strategy Group (AWMSG) Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Infliximab (Remsima®) Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG (...) Secretariat Assessment Report Advice No. 2254. 2015 Authors' conclusions Infliximab (Remsima®) is recommended as an option for restricted use within NHS Wales. Infliximab (Remsima® should be prescribed within its licensed indications in accordance with NICE or AWMSG guidance for infliximab (Remicade®), the reference product. Infliximab (Remsima®)should be prescribed by brand name to avoid automatic substitution and therefore help with pharmacovigilance. Final publication URL Indexing Status Subject

Health Technology Assessment (HTA) Database.2015

30. Infliximab (Inflectra®)

Infliximab (Inflectra®) Infliximab (Inflectra®) Infliximab (Inflectra®) All Wales Medicines Strategy Group (AWMSG) Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Infliximab (Inflectra®) Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG (...) Secretariat Assessment Report Advice No. 2253. 2015 Authors' conclusions Infliximab (Inflectra®) is recommended as an option for restricted use within NHS Wales. Infliximab (Inflectra® should be prescribed within its licensed indications in accordance with NICE or AWMSG guidance for infliximab (Remicade®), the reference product. Infliximab (Inflectra®)should be prescribed by brand name to avoid automatic substitution and therefore help with pharmacovigilance. Final publication URL Indexing Status Subject

Health Technology Assessment (HTA) Database.2015

33. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy

Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy Infliximab, adalimumab and golimumab Infliximab, adalimumab and golimumab for treating moder for treating moderately to se ately to sev verely activ erely active e ulcer ulcerativ ative colitis after the failure of e colitis after the failure of con conv ventional ther entional therap apy y T echnology appraisal guidance Published: 25 February 2015 (...) and their patients wish to use it, in accordance with the NHS Constitution. They should do so in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Infliximab, adalimumab

National Institute for Health and Clinical Excellence - Technology Appraisals2015

34. Switching from Innovator to Biosimilar (Subsequent Entry) Infliximab

Switching from Innovator to Biosimilar (Subsequent Entry) Infliximab TITLE: Switching from Innovator to Biosimilar (Subsequent Entry) Infliximab: A Review of the Clinical Effectiveness, Cost-Effectiveness, and Guidelines DATE: 26 February 2015 CONTEXT AND POLICY ISSUES Infliximab (INX) is a chimeric murine monoclonal antibody that acts against tumour necrosis factor alpha (TNF-alpha). 1 TNF inhibition with biologic agents, including INX, play a major role in contemporary management (...) product, Switching from Innovator to Biosimilar Infliximab 2 extrapolation may be made to other indications for which the innovator is approved. 12,15,16 It is important to note that Health Canada does not consider biosimilar INX to be interchangeable with innovator INX. 7 Presently, the Canadian Rheumatology Association and the Canadian Association of Gastroenterology recommend against interchanging or substituting innovator and biosimilar agents in clinical practice. 2,18 The availability

Canadian Agency for Drugs and Technologies in Health - Rapid Review2015

35. Infliximab (Inflectra) - rheumatoid arthritis, Crohn?s disease, ulcerative colitis, psoriatic arthritis and psoriasis

Infliximab (Inflectra) - rheumatoid arthritis, Crohn?s disease, ulcerative colitis, psoriatic arthritis and psoriasis Final Appraisal Recommendation Advice No: 4214 – December 2014 Infliximab (Inflectra ® ? ) 100 mg powder for concentrate for solution for infusion Submission by Hospira UK Ltd Additional note(s): ? Please refer to the Summary of Product Characteristics for the full licensed indication. ? Please refer to the NICE website for full guidance on NICE recommendations, including any (...) specific restrictions on the use of the technology. ? In accordance with EMA guidance, the licence for the use of infliximab (Inflectra ® ? ) in rheumatoid arthritis, Crohn’s disease, ulcerative colitis, psoriatic arthritis and psoriasis was granted on the basis of assumed bioequivalence. ? Due to the potential for small differences between biosimilars from different manufacturers and/or the reference product infliximab (Remicade ® ), post-marketing pharmacovigilance is essential

All Wales Medicines Strategy Group2015

36. Infliximab (Remsima) - rheumatoid arthritis, Crohn?s disease, ulcerative colitis, psoriatic arthritis and psoriasis

Infliximab (Remsima) - rheumatoid arthritis, Crohn?s disease, ulcerative colitis, psoriatic arthritis and psoriasis Final Appraisal Recommendation Advice No: 4314 – December 2014 Infliximab (Remsima ® ? ) 100 mg powder for concentrate for solution for infusion Submission by Celltrion Healthcare Ltd/Napp Pharmaceuticals Ltd Additional note(s): ? Please refer to the Summary of Product Characteristics for the full licensed indication. ? Please refer to the NICE website for full guidance on NICE (...) recommendations, including any specific restrictions on the use of the technology. ? In accordance with EMA guidance, the licence for the use of infliximab (Remsima ® ? ) in rheumatoid arthritis, Crohn’s disease, ulcerative colitis, psoriatic arthritis and psoriasis was granted on the basis of assumed bioequivalence. ? Due to the potential for small differences between biosimilars from different manufacturers and/or the reference product infliximab (Remicade ® ), post-marketing pharmacovigilance is essential

All Wales Medicines Strategy Group2015

37. Use of anti-infliximab antibody levels to monitor infliximab treatment in patients with inflammatory bowel disease (IBD)

Use of anti-infliximab antibody levels to monitor infliximab treatment in patients with inflammatory bowel disease (IBD) Use of anti-infliximab antibody levels to monitor infliximab treatment in patients with inflammatory bowel disease (IBD) Use of anti-infliximab antibody levels to monitor infliximab treatment in patients with inflammatory bowel disease (IBD) HAYES, Inc. Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality (...) of this assessment has been made for the HTA database. Citation HAYES, Inc.. Use of anti-infliximab antibody levels to monitor infliximab treatment in patients with inflammatory bowel disease (IBD) Lansdale: HAYES, Inc.. Healthcare Technology Brief Publication. 2015 Final publication URL The report may be purchased from: Indexing Status Subject indexing assigned by CRD MeSH Antibodies, Monoclonal; Humans; Inflammatory Bowel Diseases; Infliximab; Monitoring, Physiologic Language Published English Country

Health Technology Assessment (HTA) Database.2015

39. Remicade (infliximab Janssen Biotech Inc.) for first-line treatment of pediatric crohn's disease

Remicade (infliximab Janssen Biotech Inc.) for first-line treatment of pediatric crohn's disease Remicade (infliximab; Janssen Biotech Inc.) for first-line treatment of pediatric crohn's disease Remicade (infliximab; Janssen Biotech Inc.) for first-line treatment of pediatric crohn's disease Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Remicade (infliximab

Health Technology Assessment (HTA) Database.2014

40. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial.

Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial. BACKGROUND: Kawasaki disease, the most common cause of acquired heart disease in developed countries, is a self-limited vasculitis that is treated with high doses of intravenous immunoglobulin. Resistance to intravenous immunoglobulin in Kawasaki disease increases the risk of coronary artery aneurysms. We assessed whether the addition of infliximab to standard (...) therapy (intravenous immunoglobulin and aspirin) in acute Kawasaki disease reduces the rate of treatment resistance. METHODS: We undertook a phase 3, randomised, double-blind, placebo-controlled trial in two children's hospitals in the USA to assess the addition of infliximab (5 mg per kg) to standard therapy. Eligible participants were children aged 4 weeks-17 years who had a fever (temperature ≥38·0°C) for 3-10 days and met American Heart Association criteria for Kawasaki disease. Participants were

Lancet2014